Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors

Core Insights - Illumina, Inc. announced changes to its Board of Directors, with Scott Gottlieb elected as non-executive Chair and Keith Meister joining the board, while Stephen MacMillan will retire [1][2] Group 1: Board Changes - Scott Gottlieb, MD, has been elected as the non-executive Chair of Illumina's Board, having served since 2020 [1][2] - Keith Meister, founder and Chief Investment Officer of Corvex Management, will join the Board on March 28, 2025 [1] - Stephen MacMillan, who joined the board in June 2023, has decided to retire in preparation for the upcoming annual meeting of shareholders [1] Group 2: Statements from Board Members - Dr. Gottlieb expressed gratitude towards MacMillan for his contributions and emphasized the importance of advancing the company's mission and driving profitable growth [2] - MacMillan reflected positively on Illumina's achievements in genomics and expressed confidence in the board and management team [2] - Meister highlighted Illumina's strategy to expand its role in genomics and expressed confidence in the company's ability to accelerate revenue growth [2] Group 3: Background of Board Members - Scott Gottlieb served as the 23rd Commissioner of the U.S. FDA and is currently a Partner at New Enterprise Associates, with a strong background in public health and policy [3] - Keith Meister founded Corvex Management in 2010 and serves on multiple boards, bringing extensive investment experience to Illumina [4] Group 4: Company Overview - Illumina is a global leader in DNA sequencing and array-based technologies, focusing on innovation to improve human health [5] - The company's products are utilized across various applications, including life sciences, oncology, reproductive health, and agriculture [5]